PROPOFOL-LIPURO
Main information
- Trade name:
- PROPOFOL-LIPURO 2% propofol 1000 mg/50 mL emulsion for injection bottle
- Active ingredient:
- Propofol
- Available from:
- B Braun Australia Pty Ltd
- INN (International Name):
- Propofol
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- Patient Information leaflet
-
- for healthcare professionals:
- Summary of Product characteristics
-
- for the general public:
- Public Assessment Report
-
Localization
- Available in:
-
Australia
- Language:
- English
Other information
Status
- Source:
- Dept. of Health,Therapeutic Goods Administration - Australia
- Authorization number:
- 220084
- Last update:
- 08-10-2017
Public Assessment Report
Public Summary
Summary for ARTG Entry:
220084
PROPOFOL-LIPURO 2% propofol 1000 mg/50 mL emulsion for injection bottle
ARTG entry for
Medicine Registered
Sponsor
B Braun Australia Pty Ltd
Postal Address
PO Box 6221,BAULKHAM HILLS DC, NSW, 2153
Australia
ARTG Start Date
10/03/2015
Product category
Medicine
Status
Active
Approval area
Drug Safety Evaluation Branch
Conditions
Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods
Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered
or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Products
1. PROPOFOL-LIPURO 2% propofol 1000 mg/50 mL emulsion for injection bottle
Product Type
Single Medicine Product
Effective date
18/04/2017
Warnings
See Product Information and Consumer Medicine Information for this product
Standard Indications
Specific Indications
Because of the difficulty in titrating small volumes, Propofol-Lipuro 2% should not be used in children aged from one month to 3 years.,Induction of
General Anaesthesia in Children and Adults
Propofol-Lipuro is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and
older.,Maintenance of General Anaesthesia in Children and Adults
Propofol-Lipuro is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and
older.,Propofol-Lipuro 1% may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not
exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,Propofol has no analgesic properties.,Use for Sedation During Intensive
Care in Adults
Propofol-Lipuro may also be used in patients >16 years for sedation of ventilated patients receiving intensive care.,Conscious Sedation for Surgical and
diagnostic Procedures
Propofol-Lipuro may also be used for monitored conscious sedation for surgical and diagnostic procedures in,·Propofol-Lipuro 1%: adults and children
aged one month and older.
·Propofol-Lipuro 2%: adults and children aged 3 years and older.
Additional Product information
Container information
Type
Material
Life Time
Temperature
Closure
Conditions
Bottle
Glass Type II Clear
18 Months
Store below 25
degrees Celsius
Neither child resistant
closure nor restricted
flow insert
Do not Freeze
Protect from Light
Pack Size/Poison information
Pack Size
Poison Schedule
10 x 100 mL
(S4) Prescription Only Medicine
Components
1. PROPOFOL-LIPURO 2% propofol 1000 mg/50 mL emulsion for injection bottle
Dosage Form
Injection, emulsion
Route of Administration
Intravenous
Visual Identification
Milky white oil-in-water emulsion in a colourless glass infusion bottle,
sealed with a grey rubber stopper and aluminium seal with red
polypropylene flip-off insert
Active Ingredients
Propofol
20 mg/mL
© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior
written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.
Public Summary
Page 1 of
Produced at 22.11.2017 at 11:31:16 AEDT
This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information
Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation
B.Braun Australia Pty Ltd
Page 1
CONSUMER MEDICINE INFORMATION
Propofol-Lipuro 1% and 2%
1. What is in this leaflet
This leaflet contains some common questions about Propofol-Lipuro.
It does not contain all the available information.
It does not take the place of talking to your doctor or pharmacist
All medicines have risks and benefits. Your doctor or pharmacist has weighed the risk of
you taking this medicine against the benefits they expect it will have for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
2. What is Propofol-Lipuro used for?
It is a short-acting sleep inducing medicinal product used to start and sustain a general
anaesthesia.
It is used to induce sleep or lower your level of consciousness (as a sedative) during intensive
care or during diagnostic or surgical procedures.
3. Before you are given Propofol-Lipuro
When you must not be given Propofol-Lipuro
Do not use Propofol-Lipuro:
if you are allergic (hypersensitive) to Propofol or any of the other ingredients of
Propofol-Lipuro
if you are allergic (hypersensitive) to soya or peanut
Take special care with Propofol-Lipuro if:
you have a disorder in which your body does not handle fat properly
you have any other health problems which require much caution in the use of fat
emulsions
you are very overweight
your blood volume is too low (hypovolaemia)
you are very weak or have heart, circulatory, kidney or liver problems
you have high pressure within in the skull and low blood pressure in the arteries
you have problems with your breathing
you have epilepsy
you are undergoing some procedures where spontaneous movements are particularly,
undesirable.
Please tell your doctor if you have one of these diseases or conditions.
Do not give Propofol-Lipuro in children of one month of age or younger as a general anaesthetic.
B.Braun Australia Pty Ltd
Page 2
Do not give Propofol-Lipuro 2% in children under 3 years of age.
Do not give Propofol-Lipuro in children 16 years or younger as a sedation during intensive
care.
The use of Propofol-Lipuro is not recommended in newborn infants
It will not be used when you are receiving electroconvulsive therapy (electric shock treatment in
cases of severe long lasting epileptic attacks.
If you are receiving other lipids by a drip into your vein at the same time your doctor will
pay attention to your total daily fat intake.
Propofol will be administered to you by a physician trained in anaesthesia or intensive
care. You will be constantly monitored during anaesthesia and waking-up time.
If you experience signs of the so called ‘propofol infusion syndrome’ ( a doctor must be
called if the following happen) your doctor will decrease the dosage of propofol or will
switch to an alternative drug.
Taking or using other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines,
including medicines obtained without a prescription.
Some medicines may depress your breathing or your blood circulation when combined with
Propofol or prolong the effect of Propofol:
Painkillers, benzodiazepine tranquillisers, narcotic gases, some local anaesthetics, fentanyl, other
medicinal products usually given before operations.
On the other hand, the sedative effect of some of these medicinal products may become stronger.
When given together with Propofol, certain medicines used for muscle relaxation
(suxamethonium) or as antidote (neostigmin) may depress heart function.
Occurrence of a specific organic changes in the brain (leucoencephalopathy) has been reported in
patients having received fat emulsions such as Propofol-Lipuro together with ciclosporin (a
medicine used to suppress rejection reactions after organ transplantation and to suppress
overreactions of the immune system).
Make sure that your doctor knows if you are taking any of these medicinal products.
Using Propofol-Lipuro with food and drink
Alcohol and Propofol make the sedative effects of each other stronger. Therefore you should not
drink alcohol just before or just after you have Propofol-Lipuro.
Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.
Propofol-Lipuro should not be used during pregnancy.
B.Braun Australia Pty Ltd
Page 3
If you are breast-feeding your child you should stop nursing and discard breast milk for 24 hours
after you have received Propofol-Lipuro. Studies in breast-feeding women showed that Propofol
is excreted in small amounts into the milk.
Driving and using machines
You should not drive or operate machinery for a while after you have had an injection or infusion
of Propofol-Lipuro. Your doctor will tell you how long you must wait before you drive or use
machinery again.
Your doctor will advise you
if you should be accompanied when you are leaving.
when you can drive and use machinery again.
on the use of other tranquillizing drugs (e.g. tranquillizers, strong pain killers,
alcohol).
Important information about some of the ingredients of Propofol-Lipuro
This medicinal product contains less than 1 mmol (23 mg) sodium in 100 mL, that is, it is
essentially ‘sodium free’.
4. How to use Propofol-Lipuro
Propofol-Lipuro will only be given by anaesthetists or by specially trained doctors in an intensive
care unit.
Dosage
The dose you are given will vary depending on your age, body weight and physical condition.
The doctor will give the correct dose to start and to sustain anaesthesia or to achieve the required
level of sedation, by carefully watching your responses and vital signs (pulse, blood pressure,
breathing, etc).
The doctor will also observe limits of the time of application, if necessary.
Propofol-Lipuro will usually be given by injection when used to induce general anaesthesia and
by continuous infusion (a slower, longer injection) when used to maintain general anaesthesia. It
may given as an infusion either diluted or undiluted. When used as a sedative it will usually be
given by infusion.
Propofol-Lipuro will only be given for a maximum of 7 days.
Method of administration
You will receive Propofol-Lipuro by intravenous injection or infusion, that is, through a needle or
small tube placed in one of your veins.
Because Propofol
Lipuro does not contain preservatives, an infusion from one vial or bottle of
Propofol
Lipuro will not last longer than 12 hours..
Your circulation and breathing will be constantly monitored while you are being given the
injection or infusion.
Overdose
B.Braun Australia Pty Ltd
Page 4
If you received more Propofol-Lipuro then you should
It is unlikely that this occurs because the doses you receive are very carefully controlled.
If you accidentally got an overdose, this could lead to depression of heart function, circulation
and breathing. In this case your doctor will employ any necessary treatment immediately.
If you have any further questions on the use of this product, ask your doctor or pharmacist
5. Possible Side Effects
Like all medicines, Propofol-Lipuro emulsion for injection or infusion can cause side effects,
although not everybody gets them.
Common (may affect up to 1 in 10 people):
Low blood pressure that might occasionally need infusion of fluids and reduction of
the speed of administration of propofol.
Too low heartbeat that might be serious in rare cases.
Rare
(may affect up to 1 in 1,000 people):
Convulsions like in epilepsy
Very rare (may affect up to 1 in 10,000 people):
Allergic reactions including swelling of the face, tongue or throat, wheezing breath,
skin redness and low blood pressure
There have been cases of unconsciousness occurring after operations. You will
therefore be carefully observed during the waking-up time.
Water on lungs (lung oedema) after administration of propofol
Inflammation of the pancreas.
Not known
(frequency cannot be estimated from the available data):
There have been reports of isolated cases of severe adverse reactions presenting as a
combination of the following symptoms: breakdown of muscle tissue, accumulation
of acidic (sour) substances in the blood, abnormally high blood potassium level, high
blood fat levels, abnormalities in the electrocardiogram (Brugada-type ECG), liver
enlargement, irregular heart-beat, kidney failure and heart failure. This has been
called the
“propofol infusion syndrome”
. Some of the affected patients eventually
died. These effects have only been seen in patients in intensive care with doses
higher than 4 mg of propofol per kg body weight per hour. See also section 2,
‘Warnings and precautions’.
Other side effects are:
Very common (affects more than 1 treated patient of 10):
Pain at the injection site occurring during the first injection. The pain may be
reduced by injecting propofol into larger veins of the forearm. Injection of lidocaine
(a local anaesthetic) and propofol at the same time also helps to reduce the pain at the
injection site.
Common (may affect up to 1 in 10 people):
B.Braun Australia Pty Ltd
Page 5
Short interruption of breathing
Headache during the time of recovery
Sickness or vomiting during the time of recovery
Uncommon (may affect up to 1 in 100 people):
Blood clots in veins or inflammation of veins
Very rare
(may affect up to 1 in 10,000 people):
Loss of sexual control during the time of recovery
Abnormal colour of urine after longer lasting administration of propofol
Cases of fever after an operation
Not known (frequency cannot be estimated from the available data):
Involuntary movements
Abnormally good mood
Drug abuse
Failure of the heart
Breakdown of muscle tissue has been reported very rarely in cases where propofol
has been given at greater doses than recommanded for sedation in intensive care
units
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet.
6. Storage
Keep out of the reach and sight of children.
Do not use Propofol-Lipuro after the expiry date which is stated on the label and the carton after
EXP. The expiry date refers to the last day of that month.
Keep ampoules in the outer carton in order to protect from light. Store below 25°C. Do not freeze.
Propofol-Lipuro must be used immediately after opening the ampoule, vial or bottle.
Do not use Propofol-Lipuro if two separate layers can be seen after shaking the product.
The following information is intended for medical or healthcare professionals only:
The containers are for single use in one patient only.
Any unused emulsion must be thrown away at the end of administration.
The containers must be shaken before use.
7. Product Description
What
Propofol-Lipuro
looks like
It is a milky-white oil-in water emulsion which comes in the following:
Propofol-Lipuro 1%:
20mL glass ampoule
B.Braun Australia Pty Ltd
Page 6
20mL colourless glass vial, sealed with a grey rubber stopper and aluminium seal with a blue
polypropylene flip
off insert
50mL colourless glass infusion bottles, sealed with a grey rubber stopper and aluminium seal
with a blue polypropylene flip
off insert
100mL colourless glass infusion bottles, sealed with a grey rubber stopper and aluminium seal
with a blue polypropylene flip
off insert
Propofol-Lipuro 2%:
50mL colourless glass infusion bottles, sealed with a grey rubber stopper and aluminium seal
with a red polypropylene flip
off insert
Ingredients:
Propofol-Lipuro 1%
Active ingredient:
Propofol
1 mL contains 10 mg of Propofol.
Inactive ingredients:
Soya oil,
Medium-chain triglycerides,
Egg lecithin,
Glycerol,
Sodium oleate,
Water for injections
Propofol-Lipuro 2%
Active ingredient:
Propofol
1 mL contains 20 mg of Propofol.
Inactive ingredients:
Soya oil,
Medium-chain triglycerides,
Egg lecithin,
Glycerol,
Sodium oleate,
Water for injections
Australian registration number:
Propofol-Lipuro 1%:
20mL ampoule
AUST R 142906
20mL vial
AUST R 220082
50mL bottle
AUST R 220083
Propofol-Lipuro 2%:
50mL bottle
AUST R 220084
100mL bottle
AUST R 220081
8. Sponsor Details
B. Braun Australia Pty Ltd
17 Lexington Drive
Bella Vista NSW 2156
Australia
Toll Free Number: 1800 251 705
9. Date of Information
This leaflet was updated in August 2014
- Access to this document is only available to registered users.
Register now for full access
There are no safety alerts related to this product.
13-9-2018

Propofol: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00002555/201711
Europe - EMA - European Medicines Agency
13-9-2018

Propofol: List of nationally authorised medicinal products - PSUSA/00002555/201711
Europe - EMA - European Medicines Agency